Stargardt disease
Stargardt disease is the most common form of inherited juvenile macular degeneration — a bilateral, progressive central vision loss most often caused by biallelic mutations in the ABCA4 gene (autosomal recessive), with rarer dominant forms via ELOVL4 and PROM1. Onset typically falls between ages 6 and 20, though presentation can extend later. Trajectory: gradual loss of central vision, color vision changes, photophobia, characteristic pisciform yellow flecks at the posterior pole on funduscopy progressing to bull's-eye macular atrophy. Diagnostics: dilated funduscopy, OCT, fundus autofluorescence (the 'dark choroid sign' on fluorescein angiography is a recognized hallmark), full-field ERG, EOG, genetic testing across ABCA4 + ELOVL4 + PROM1. No FDA-approved disease-modifying therapy exists as of 2026. VITAMIN A AVOIDANCE is the load-bearing safety thread — vitamin A is the substrate that becomes toxic A2E in ABCA4-related Stargardt, and supplementation can accelerate disease progression. UV protection + sun avoidance + low vision rehabilitation are standard. Emixustat SeaSTAR Phase 3 FAILED 2022. Gildeuretinol (ALK-001 deuterated vitamin A) Phase 3 TEASE positive 2024 — leading DMT candidate. AAV-ABCA4 gene therapy (StarGen + OCU410 + dual-vector approaches; ABCA4 too large for single AAV) and hESC-RPE transplant (Astellas/Ocata ASTRO-01-Stargardt + UCL/King's + jCyte) in earlier-phase trials. Foundation Fighting Blindness principal US patient organization. Genetic counseling required. No peptide has a defensible Stargardt discovery-card case. Twenty-ninth deliberate non-elevation.
What changes during this transition
Stargardt disease sits in a category the peptide-adjacent supplement and clinic landscape handles particularly badly: a serious, progressive, hereditary diagnosis with thin standard-of-care, no FDA-approved disease-modifying therapy as of 2026, and a patient population — young people losing central vision over years to decades — that is desperately motivated to find something, anything, that might slow the trajectory. That combination is exactly the conditions under which community framing of peptides as 'nerve healing' or 'mitochondrial protection' or 'NAD+ optimization' gets stretched far beyond the underlying evidence. The substrate page exists to give Juno's /ask surface honest grounding when users with Stargardt — or family members, or clinicians supporting them — probe the library on peptides they've encountered in their search. The honest answer for every peptide on this page is some variant of 'no published evidence in Stargardt, and the cross-indication leap from where evidence exists to this hereditary monogenic retinal disease does not carry.' BPC-157's tendon and gut and CNS injury literature does not extend to ABCA4-mediated bisretinoid toxicity. SS-31's 2025 FDA approval for Barth syndrome cardiomyopathy and its ReCLAIM-2 dry-AMD signal do not propagate to a different macular degeneration with a different upstream driver — Rule 6 in its most load-bearing form. NMN's NAD+-decline narrative may be biologically real for general aging without being a Stargardt intervention. Cerebrolysin's multi-jurisdictional neuroprotection register, which is genuinely real for stroke and TBI and dementia in the jurisdictions where it's registered, does not include hereditary retinal degeneration in any of those jurisdictions. PEDF is the most mechanistically plausible candidate from the published preclinical retinal literature and simultaneously the one with the largest gap between 'interesting preclinical biology' and 'available clinical intervention.' The dominant intervention landscape is elsewhere. Gildeuretinol (ALK-001, deuterated vitamin A) reported positive Phase 3 results in 2024 for geographic atrophy lesion growth slowing and is reading positively in the ABCA4-Stargardt-specific Phase 3 program — this is the leading disease-modifying-therapy candidate as of 2026 and the trial pathway most Stargardt patients should be asking their retinal specialist about. AAV-based ABCA4 gene therapy programs (StarGen, OCU410, and platform extensions) are working through the challenge that ABCA4 is too large for a single AAV vector, driving dual-vector approaches. Astellas Institute / Ocata Therapeutics's hESC-derived RPE transplant program (ASTRO-01-Stargardt) and the UCL / King's College + jCyte programs sit in earlier-phase territory but are real. Foundation Fighting Blindness is the principal US patient organization connecting Stargardt patients to these pathways. The load-bearing safety thread on this substrate page — and the load-bearing safety thread for every Stargardt patient evaluating any supplement, any peptide, any wellness intervention — is vitamin A avoidance. Stargardt's molecular pathology runs through vitamin A metabolism: ABCA4 normally clears all-trans-retinaldehyde from photoreceptor disc membranes, mutations cause toxic bisretinoid A2E to accumulate in the RPE, and that accumulation drives RPE atrophy and photoreceptor death. Supplemental vitamin A — at supraphysiologic doses, in retinol-supplement form, in high-dose multivitamins, in some longevity stacks, in liver-rich diets — is the substrate that becomes A2E, and supplementation can accelerate disease progression. This is not a theoretical concern; it is the central supplement-safety question for every Stargardt patient. Any peptide-clinic intake or wellness-supplement conversation that does not surface this question is missing the load-bearing point. The peptide_slugs array is intentionally empty for Stargardt. None of the peptides in the Juno library is editorially appropriate to elevate as a discovery card here — the substrate exists for /ask grounding when users probe, not to signal to Stargardt patients that any of these peptides is a discovery option. The honest answer in 2026 is that the discovery landscape for Stargardt is gildeuretinol's clinical-trial pathway, AAV-ABCA4 gene therapy enrollment, hESC-RPE transplant programs, Foundation Fighting Blindness's registry, and the surveillance + low vision rehabilitation + vitamin A avoidance + UV protection scaffolding that good retinal specialists already provide. None of that is a peptide intervention.
Important caveat
Stargardt disease requires retinal-specialist-led management — a retinal specialist (ophthalmologist with retinal subspecialty training, ideally connected to an academic medical center with hereditary retinal disease expertise) sets the surveillance cadence, interprets the OCT and FAF imaging, coordinates genetic testing and counseling, and connects patients to the active clinical-trial landscape. Peptide clinics, wellness clinicians, longevity practitioners, and community-pharmacy compounders are not substitutes for this care and should not be supervising any intervention in a Stargardt patient without explicit retinal-specialist coordination. VITAMIN A AVOIDANCE is the load-bearing safety thread for every Stargardt patient and the single most important supplement-safety question on this page. Stargardt's molecular mechanism — particularly in the ABCA4-related forms that comprise the majority of cases — runs through vitamin A metabolism: ABCA4 normally clears all-trans-retinaldehyde from photoreceptor disc membranes, ABCA4 mutations cause the toxic bisretinoid A2E to accumulate in the RPE, and exogenous vitamin A at supraphysiologic doses becomes additional substrate for that toxic accumulation. High-dose vitamin A supplementation, retinol-supplement products, high-dose multivitamins containing vitamin A or beta-carotene, longevity supplement stacks with vitamin A components, and high-vitamin-A foods at supraphysiologic levels (liver-rich diets, very high-dose carotenoid supplementation) can accelerate disease progression. Every supplement label a Stargardt patient considers — including multivitamins, greens powders, metabolic-health stacks, eye-health formulations sold to the general macular degeneration market, and longevity products — must be read for vitamin A and beta-carotene content before any decision. The peptides themselves on this substrate page are not vitamin A and do not metabolize to retinaldehyde, but the broader supplement-stack conversation that surrounds peptide use is exactly where vitamin A exposure tends to slip in unflagged. The retinal specialist managing the Stargardt is the right person to review the full stack. Clinical-trial landscape is the actual disease-modifying-therapy conversation: gildeuretinol (ALK-001) Phase 3 TEASE positive 2024 — leading DMT candidate; AAV-based ABCA4 gene therapy (StarGen, OCU410, dual-vector approaches addressing the ABCA4-too-large-for-single-AAV constraint); hESC-derived RPE transplant programs (Astellas Institute / Ocata Therapeutics ASTRO-01-Stargardt; UCL / King's College + jCyte); Foundation Fighting Blindness clinical-trial registry. Emixustat SeaSTAR Phase 3 FAILED 2022 — landscape data point worth knowing. Genetic counseling is part of standard-of-care workup, not optional — Stargardt is autosomal recessive in most cases, with family-planning implications for siblings, carrier-status partners, and offspring. UV protection (UV-blocking sunglasses, wide-brim hats, behavioral avoidance of bright-light exposure) reduces light-driven photoreceptor stress. Smoking cessation and cardiovascular health support general retinal vascular health. Low vision rehabilitation — visual aids, orientation and mobility training, occupational therapy, screen-reading and magnification tools — preserves function as central vision declines and should be engaged early rather than late. WADA athletes: BPC-157 (S0) prohibited at all times — no Stargardt use case anyway. Pregnancy: Stargardt does not require disease-specific pregnancy management, but the vitamin A avoidance question becomes more complex because prenatal vitamins typically contain vitamin A; coordinate with retinal specialist + maternal-fetal medicine to find a low-vitamin-A prenatal formulation. This substrate is editorial honesty for /ask probing; it is not a recommendation to use any of these peptides in Stargardt.
Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.